Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients

Davide Caimmi; Nicolas Martocq; Delphine Trioleyre; Catherine Guinet; Sylvain Godreuil; Thomas Daniel; Raphael Chiron

doi:10.1093/ofid/ofy034

Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients

Open Forum Infect Dis. 2018 Feb 17;5(3):ofy034. doi: 10.1093/ofid/ofy034. eCollection 2018 Mar.

Authors

Davide Caimmi^{1

2}, Nicolas Martocq¹, Delphine Trioleyre¹, Catherine Guinet¹, Sylvain Godreuil³, Thomas Daniel¹, Raphael Chiron¹

Affiliations

¹ Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Univ Montpellier, France.
² Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Sorbonne Université, French Institute of Health and Medical Research (INSERM), Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
³ Department of Microbiology, University Hospital of Montpellier, France.

Abstract

Mycobacterium abscessus is difficult to eradicate. At the Montpellier CF Center, we prescribed liposomal amikacin for inhalation to 5 patients with M abscessus infection. The 3 patients who completed the treatment did not have any respiratory exacerbation, showed negative cultures for M abscessus in their sputum, and stabilized their spirometric functions.

Keywords: Mycobacterium abscessus; cystic fibrosis; liposomal amikacin; nontuberculous mycobacteria; treatment.